PostDose.

Guides

Brand vs. Compounded GLP-1: How to Tell If Your Clinic Is Legal in 2026

The GLP-1 shortage that made bulk compounding legal is over. Here's what the FDA's own rules say about brand-name vs. compounded semaglutide and tirzepatide today, and the red flags we check for in every Houston clinic.

For roughly two years, the FDA’s official drug shortage list for semaglutide and tirzepatide gave state-licensed pharmacies a legal opening to compound GLP-1 medications in bulk, sidestepping the patent-protected formulations sold as Wegovy, Ozempic, Zepbound, and Mounjaro. That opening is closed. The FDA determined the tirzepatide injection shortage resolved on October 2, 2024 (reconfirmed December 19, 2024), and the semaglutide injection shortage resolved February 21, 2025. Compounders that kept dispensing under the shortage exemption past the wind-down deadlines — February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide, both for 503A pharmacies — are now preparing a drug the law generally treats as “essentially a copy” of an FDA-approved product, which section 503A restricts outside a documented, patient-specific medical need.

The rule isn’t “compounding is illegal.” Under sections 503A and 503B of the Federal Food, Drug and Cosmetic Act, a state-licensed pharmacy or physician can still compound a GLP-1 for a specific patient — someone with a documented allergy to an inactive ingredient in the brand product, say, or a dosage form the manufacturer doesn’t make. What the law restricts is routine, bulk compounding of a drug that’s commercially available in essentially the same form. On April 1, 2026, the FDA sharpened that standard further, clarifying that a compounded product combining semaglutide with another ingredient — vitamin B12 is the FDA’s own example — still counts as “essentially a copy” of the brand drug if the dose is within 10% of the approved strength and given by the same route. Renaming the product a “semaglutide blend” doesn’t change the analysis.

Red flags we check for

When we audit a clinic for the PostDose directory, three patterns disqualify it every time.

Research-only peptides sold for human use. The FDA has separately warned that products containing semaglutide, tirzepatide, or retatrutide are sometimes sold with labels claiming “for research purposes” or “not for human consumption,” while being marketed with human dosing instructions. That mislabeling is a legal workaround, not a safety measure — retatrutide and cagrilintide in particular are not FDA-approved for any human use and cannot legally be compounded at all.

No named, verifiable prescriber. “Our medical team,” with no name we can check against the federal NPI registry, tells us nothing about who is actually writing the prescription.

Vague drug language. A weight-loss page that describes “GLP-1 receptor agonists” generically, without naming Wegovy, Ozempic, Zepbound, or Mounjaro, and without disclosing whether the product is compounded — a pattern we flag as under verification until the clinic clarifies.

What a clean pass looks like

The clinics we mark verified name their prescriber, and we confirm that name is active in the NPI registry for Texas. They’re explicit about medication sourcing — brand-name GLP-1s, or a documented patient-specific compounding rationale — not a generic “semaglutide program” with no detail behind it. In our most recent Houston sweep, we evaluated 80 clinics and excluded 41 outright, most often for exactly the two failures above: compounded GLP-1s marketed as the primary product with no sourcing disclosure, or peptide menus built around research-only compounds like BPC-157 or CJC-1295 with no FDA-approved indication.

Before your first appointment

Ask the clinic directly: is this brand-name medication, or compounded? If compounded, what’s the documented medical reason? Is the prescriber’s name searchable in the NPI registry? A clinic that answers plainly, in writing, is behaving the way the law expects a state-licensed pharmacy or physician to behave. One that dodges the question is telling you something too.

See our full verification standard and browse verified GLP-1 and peptide clinics in Houston.

Sources: U.S. Food and Drug Administration, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize”, content current as of April 1, 2026. FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, content current as of June 15, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.